CD3×CD19双特异性抗体治疗系统性红斑狼疮的1期试验
该首次人体1期试验静脉给药组纳入12例活动性SLE患者,评估CD3×CD19双特异性T细胞衔接器A-319的安全性,随访52周。A-319安全性良好,无治疗相关严重不良事件,CRS以1级为主;探索性疗效显示12个月时80%达LLDAS、60%达DORIS,并伴SLEDAI-2K评分、自身抗体滴度和蛋白尿持续下降。
要点
- A-319在活动性SLE中安全性良好,未见治疗相关严重不良事件或≥3级CRS。
- 探索性疗效:12个月时80%(8/10)达LLDAS,60%(6/10)达DORIS。
- 单细胞RNA测序提示免疫重编程机制与CD19 CAR-T治疗SLE相似。
核心结论
- CD3×CD19双特异性T细胞衔接器A-319在活动性SLE中显示可行性、安全性和初步疗效,支持进一步开展对照关键性研究。
研究设计与样本
- 正在进行的首次人体1期试验静脉给药组,纳入12例活动性SLE患者,随访52周。
- 给药方案:先予1周 priming 剂量(0.05 μg kg-1),随后A-319 0.3-1.2 μg kg-1每周三次、持续3周。
- 主要终点为安全性和耐受性;次要终点包括药代动力学、药效学和免疫原性;疗效为探索性终点。
主要发现
- 无治疗相关严重不良事件和死亡,无≥3级细胞因子释放综合征(CRS)或神经毒性;CRS以1级为主(91.6%,11/12),血液学毒性轻微。
- 药代动力学呈线性,B细胞清除呈剂量依赖性,较高剂量组实现外周B细胞完全清除。
- 12个月时80%(8/10)患者达LLDAS,60%(6/10)达DORIS,伴SLEDAI-2K评分、自身抗体滴度和蛋白尿持续下降。
- 探索性单细胞RNA测序显示广泛免疫重编程,包括B细胞、T细胞和髓系中SLE相关干扰素反应特征的多谱系抑制,以及B细胞库接近完全重建。
关键数值与推荐
- 主要终点安全性:无治疗相关严重不良事件、死亡、≥3级CRS或神经毒性。
- CRS以1级为主:91.6%(11/12)。
- 12个月LLDAS:80%(8/10);DORIS:60%(6/10)。
临床怎么用
- A-319作为即用型T细胞衔接器,无需淋巴细胞清除化疗和自体细胞制备,可能扩大深度B细胞清除的可及人群。
- 当前数据支持在对照关键性研究中进一步评估CD3×CD19 T细胞衔接器治疗SLE。
局限性
- 样本量小(12例),疗效为探索性终点,缺乏对照组。
- 随访52周,长期安全性和持久缓解尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to a fraction of patients who might benefit. Bispecific T cell engagers (TCEs) offer a potent, off-the-shelf approach to deep B cell depletion; however, controlled clinical evaluation in rheumatic disease remains limited. Here we report results from the intravenous treatment arm of an ongoing, first-in-disease, phase 1 trial of A-319, a next-generation CD3×CD19 TCE, in 12 patients with active systemic lupus erythematosus (SLE) with 52 weeks of follow-up. Patients received A-319 (0.3-1.2 μg kg-1) three times weekly for 3 weeks after 1 week of priming doses (0.05 μg kg-1). The primary endpoint was safety and tolerability. A-319 demonstrated a favorable safety profile, with no treatment-related serious adverse events, deaths, grade 3 or higher cytokine release syndrome (CRS) or neurotoxicity; CRS was predominantly grade 1 (91.6%, 11/12), and hematologic toxicity was minimal. Secondary endpoints (pharmacokinetics, pharmacodynamics and immunogenicity) demonstrated linear pharmacokinetics and dose-dependent B cell depletion, with complete peripheral depletion in higher-dose cohorts. Among exploratory efficacy endpoints, 80% (8/10) of patients achieved Lupus Low Disease Activity State (LLDAS), and 60% (6/10) achieved Definition of Remission in SLE (DORIS) at 12 months, accompanied by sustained reductions in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores, autoantibody titers and proteinuria. Exploratory serial single-cell RNA sequencing revealed broad immune reprogramming mechanistically similar to that after CD19 CAR T cell therapy in SLE, including multi-lineage suppression of SLE-associated interferon response signatures across B cell, T cell and myeloid compartments and near-complete reconstitution of the B cell repertoire. Together, these findings demonstrate the feasibility, safety and preliminary efficacy of CD3×CD19 T cell engagement in SLE and support further clinical development of TCEs in controlled, pivotal studies. ClinicalTrials.gov identifier: NCT06400537 .
引用
- Xu J, Mei C, Guan X, et al. A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial. Nat Med. 2026. PMID: 42722888. doi:10.1038/s41591-026-04572-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。